PD 89454

structure given in first source; RN given refers to parent cpd

Also Known As:

2-(2-(3-azabicyclo(3.2.2)non-3-yl)ethyl)-5,6-dimethoxy-1,2-benzisothiazol-3(2H)-one; PD 89454 monohydrochloride; PD-89454

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Hypopigmentation (Hypomelanosis) 01/01/1989 - "Hypopigmentation was the principal manifestation of systemic toxicity when the experimental platelet aggregation inhibitor, PD-89454, was orally administered to Beagle dogs for 28 days. "

1.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)